First Page | Document Content | |
---|---|---|
Date: 2012-08-15 16:02:38Non-nucleoside reverse transcriptase inhibitors Carbamates Pyridines Sulfonamides Darunavir Etravirine Lopinavir/ritonavir Ritonavir Atazanavir Chemistry Organic chemistry Protease inhibitors | 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INTELENCE® safely and effectively. See full prescribing information for INTELENCE®.Add to Reading ListSource URL: www.accessdata.fda.govDownload Document from Source WebsiteFile Size: 957,86 KBShare Document on Facebook |
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULYZAQ safely and effectively. See full prescribing information for FULYZAQ. FULYZAQ ® (crofelemer) delayed-releasDocID: 1gtlL - View Document | |
SUPPLEMENT ARTICLE Drug-Drug Interactions in the Treatment of HCV Among People Who Inject Drugs Stefan Mauss1 and Hartwig Klinker2 1DocID: 1giaR - View Document | |
AIDS Research and Therapy BioMed Central ResearchDocID: 1aNo3 - View Document | |
MS&D logo_no qualifier_2 linesDocID: 1a8lZ - View Document | |
Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: IDocID: 1a178 - View Document |